ALLMedicine™ Alopecia Center
Research & Reviews 3,942 results
https://doi.org/10.1080/1744666X.2022.2096590
Expert Review of Clinical Immunology; Basmanav FB, Betz RC
Jul 1st, 2022 - Alopecia areata (AA) is a non-scarring, hair loss disorder and a common autoimmune-mediated disease with an estimated lifetime risk of about 2%. To date, the treatment of AA is mainly based on suppression or stimulation of the immune response. Gen...
https://clinicaltrials.gov/ct2/show/NCT04797650
Jul 1st, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that s...
https://clinicaltrials.gov/ct2/show/NCT04784533
Jul 1st, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
https://clinicaltrials.gov/ct2/show/NCT05041803
Jul 1st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...
https://clinicaltrials.gov/ct2/show/NCT05398809
Jul 1st, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...
Guidelines 3 results
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.
Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.
Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.
Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,
Drugs 298 results see all →
Clinicaltrials.gov 427 results
https://clinicaltrials.gov/ct2/show/NCT04797650
Jul 1st, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that s...
https://clinicaltrials.gov/ct2/show/NCT04784533
Jul 1st, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
https://clinicaltrials.gov/ct2/show/NCT05041803
Jul 1st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...
https://clinicaltrials.gov/ct2/show/NCT05398809
Jul 1st, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...
https://clinicaltrials.gov/ct2/show/NCT05380427
Jun 30th, 2022 - To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects; To evaluate the pharmacokinetic (PK) characteristics of CU-40101 liniment administered as a sing...
News 844 results
https://www.medscape.com/viewarticle/976527
Jul 1st, 2022 - Dermatologists, who recently celebrated the US Food and Drug Administration's (FDA's) approval of the world's first oral systemic treatment for adults with severe alopecia areata (AA), are now looking ahead to the practicalities of getting the dru...
https://www.medscape.com/viewarticle/976020
Jun 22nd, 2022 - Dr Viktor R. Curovic A one-size-fits-all approach may not be the best way to treat albuminuria in patients with diabetes. Multiple guidelines recommend a renin-angiotensin system (RAS) inhibitor (an angiotensin-converting enzyme inhibitor or angio...
https://www.mdedge.com/dermatology/article/255473/hair-nails/hair-disorder-treatments-are-evolving
Kathleen Doheny
Jun 15th, 2022 - “No matter who the patient is, whether a child, adolescent, or adult, the key to figuring out hair disease is getting a good history,” Maria Hordinsky, MD, professor and chair of the department of dermatology at the University of Minnesota, Minnea.
https://www.medscape.com/viewarticle/975487
Jun 13th, 2022 - The US Food and Drug Administration (FDA) today approved baricitinib oral tablets as the first systemic treatment for adult patients with severe alopecia areata. The disorder with the hallmark signs of patchy baldness affects more than 300,000 peo...
https://www.mdedge.com/dermatology/article/255353/atopic-dermatitis/atopic-dermatitis-options-abound-and-more-are-coming
Kathleen Doheny
Jun 10th, 2022 - For dermatologists and others treating patients with atopic dermatitis (AD), it is “an incredible time,” Lawrence F. Eichenfield, MD, said at MedscapeLive’s Women’s & Pediatric Dermatology Seminar.